Please use this identifier to cite or link to this item:
Title: The Roles of CD38 and CD157 in the Solid Tumor Microenvironment and Cancer Immunotherapy
Authors: Wo, Y.J.
Gan, A.S.P.
Lim, X.
Tay, I.S.Y.
Lim, S.
Lim, J.C.T.
Yeong, J.P.S.
Keywords: Cancer Immunotherapy
Immunotherapy Targets
TME (Tumor Microenvironment)
Issue Date: 2019
Publisher: NLM (Medline)
Citation: Wo, Y.J., Gan, A.S.P., Lim, X., Tay, I.S.Y., Lim, S., Lim, J.C.T., Yeong, J.P.S. (2019). The Roles of CD38 and CD157 in the Solid Tumor Microenvironment and Cancer Immunotherapy. Cells 9 (1). ScholarBank@NUS Repository.
Rights: Attribution 4.0 International
Abstract: The tumor microenvironment (TME) consists of extracellular matrix proteins, immune cells, vascular cells, lymphatics and fibroblasts. Under normal physiological conditions, tissue homeostasis protects against tumor development. However, under pathological conditions, interplay between the tumor and its microenvironment can promote tumor initiation, growth and metastasis. Immune cells within the TME have an important role in the formation, growth and metastasis of tumors, and in the responsiveness of these tumors to immunotherapy. Recent breakthroughs in the field of cancer immunotherapy have further highlighted the potential of targeting TME elements, including these immune cells, to improve the efficacy of cancer prognostics and immunotherapy. CD38 and CD157 are glycoproteins that contribute to the tumorigenic properties of the TME. For example, in the hypoxic TME, the enzymatic functions of CD38 result in an immunosuppressive environment. This leads to increased immune resistance in tumor cells and allows faster growth and proliferation rates. CD157 may also aid the production of an immunosuppressive TME, and confers increased malignancy to tumor cells through the promotion of tumor invasion and metastasis. An improved understanding of CD38 and CD157 in the TME, and how these glycoproteins affect cancer progression, will be useful to develop both cancer prognosis and treatment methods. This review aims to discuss the roles of CD38 and CD157 in the TME and cancer immunotherapy of a range of solid tumor types.
Source Title: Cells
ISSN: 2073-4409
DOI: 10.3390/cells9010026
Rights: Attribution 4.0 International
Appears in Collections:Students Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_3390_cells9010026.pdf4.95 MBAdobe PDF




checked on Nov 17, 2021

Page view(s)

checked on Aug 4, 2022

Google ScholarTM



This item is licensed under a Creative Commons License Creative Commons